招杰
【摘要】 目的 研究并分析采用雙歧桿菌四聯活菌片(益生菌)治療潰瘍性結腸炎的臨床效果。
方法 120例潰瘍性結腸炎患者, 通過數字隨機表法分為對照組和觀察組, 每組60例。對照組患者單用美沙拉嗪治療, 觀察組患者采用益生菌聯合美沙拉嗪治療。觀察兩組患者臨床療效、復發率及不良反應發生率。結果 治療后, 對照組患者總有效率為76.67%(46/60);觀察組患者為93.33%(56/60)。觀察組患者治療總有效率顯著高于對照組, 差異具有統計學意義(P<0.05)。對照組患者隨訪期間12例復發, 復發率為20.00%(12/60);觀察組患者隨訪期間2例復發, 復發率為3.33%(2/60), 觀察組患者復發率明顯低于對照組, 差異有統計學意義(P<0.05)。對照組患者用藥期間不良反應發生率為21.67%(13/60);觀察組患者為3.33%(2/60), 觀察組患者不良反應發生率明顯低于對照組(P<0.05)。結論 潰瘍性結腸炎患者的治療過程中, 在美沙拉嗪治療基礎上聯合使用益生菌治療能夠使患者獲得更加確切的療效, 能夠降低用藥不良反應和疾病的復發率, 值得推廣應用。
【關鍵詞】 潰瘍性結腸炎;雙歧桿菌四聯活菌片;治療效果
DOI:10.14163/j.cnki.11-5547/r.2018.01.048
【Abstract】 Objective To study and analyze the clinical effect of bifidobacterium quadruple living bacterium (probiotics) in the treatment of ulcerative colitis. Methods A total of 120 ulcerative colitis patients were divided by random number table method into control group and observation group, with 60 cases in each group. The control group was treated with mesalazine only, and the observation group was treated with probiotics and mesalazine. Observation were made on clinical efficacy, recurrence rate and incidence of adverse reactions between two groups. Results After treatment, the control group had total effective rate as 76.67% (46/60), which was 93.33% (56/60) in the observation group. The observation group had obviously higher total treatment effective rate than the control group, and the difference was statistically significant (P<0.05). The control group had 12 recurrent cases during follow-up, with recurrence rate as 20.00% (12/60), while the observation group had 2 recurrent cases during follow-up, with recurrence rate as 3.33% (2/60). The observation group had obviously lower recurrence rate than the control group, and the difference was statistically significant (P<0.05). The control group had incidence of adverse reactions during administration as 21.67% (13/60), while the observation group had incidence of adverse reactions during administration as 3.33%(2/60). The observation group had obviously lower incidence of adverse reactions than the control group (P<0.05). Conclusion In the treatment of ulcerative colitis patients, application of promethazine on the basis of mesalazine can make patients get a more definite effect, reduce the adverse reactions and the recurrence rate of the disease. It is worthy of popularization and application.
【Key words】 Ulcerative colitis; Bifidobacterium quadruple living bacterium; Treatment effect
潰瘍性結腸炎是臨床常見胃腸道疾病, 發病原因尚不明確, 患者的直腸以及結腸會發生慢性的、非特異性的炎癥反應, 并引發腹瀉、腹痛、黏液膿血便等癥狀。目前臨床多應用氨基水楊酸類、糖皮質激素或免疫抑制劑對患者進行治療干預, 能夠獲得較為理想的近期療效, 但同時會對患者的免疫系統造成較大副作用, 停藥后患者的復發率較高[1]。大部分研究者認為, 潰瘍性結腸炎的發病與遺傳、感染、環境、腸道微生物、免疫等因素有著密切關系[2]。而益生菌具備提升抗感染能力、促進機體免疫功能、維持腸道菌群平衡等效用, 在潰瘍性結腸炎中是否適用已經成為臨床研究的重點問題。在本次研究中, 給予潰瘍性結腸炎患者美沙拉嗪聯合益生菌治療, 效果顯著, 現報告如下。endprint
1 資料與方法
1. 1 一般資料 選取2015年5月~2016年5月本院收治的120例潰瘍性結腸炎患者, 通過數字隨機表法分為對照組和觀察組, 每組60例。……